ArticleEye (London, England)2023
Short-term safety and efficacy of Preserflo™ Microshunt in glaucoma patients: a multicentre retrospective cohort study.
Article in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Comparison of surgically induced astigmatism following PreserFlo MicroShunt implantation versus trabeculectomy in Japanese patients with glaucoma.Japanese journal of ophthalmology · 2026Article
- A-stream glaucoma shunt versus trabeculectomy: 1-year results on efficacy and safety.Scientific reports · 2026Article
- Two-year outcomes of PRESERFLO MicroShunt implantation in a real-world heterogeneous glaucoma cohort: a retrospective single-center study.Frontiers in ophthalmology · 2026Article
- Comparative outcomes of PreserFloTMMicroShunt in primary open-angle and pseudoexfoliative glaucoma: A matched analysis.PloS one · 2026Article
- Short-term outcomes of the PreserFlo MicroShunt in Japanese patients with exfoliation glaucoma: a comparison with primary open-angle glaucoma using propensity score matching.Japanese journal of ophthalmology · 2026Observational
- Primary PreserFlo MicroShunt Versus Trabeculectomy: Effectiveness and Safety in the Real World.Journal of clinical medicine · 2025Article
- Review
- Intraluminal 10-0 Nylon Stenting in PRESERFLO™ MicroShunt Surgery for Pseudoexfoliation Glaucoma.Journal of clinical medicine · 2025Article
- Management practices and surgical techniques for ab externo less invasive glaucoma surgery: a literature review and expert recommendations.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- Utility of intraoperative optical coherence tomography in filtration surgery using MicroShunt.Japanese journal of ophthalmology · 2025Observational
- Short-Term Safety and Efficacy of PreserFlo™ Microshunt in Patients with Refractory Intraocular Pressure Elevation After Dexamethasone Implant Intravitreal Injection.Journal of clinical medicine · 2025Article
- Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma.Scientific reports · 2025Article
- One-Year Comparison of Efficacy and Safety of PreserFlo MicroShunt with Mitomycin C Applied by Sub-Tenon Injection Versus Sponge.Ophthalmology and therapy · 2025Article
- Reinterventions After PreserFlo Implantation: A Report on Results in Clinical Practice.Journal of ophthalmology · 2025Article
- Intermediate-term impact on corneal endothelial cells and efficacy of Preserflo MicroShunt implantation in patients with open-angle glaucoma - a prospective study over two years.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Observational
- Postoperative Outcomes of PreserFlo MicroShunt in Patients with Exfoliation Glaucoma.Journal of clinical medicine · 2024Article
- Additional Guidance on the Use of the PRESERFLO™ MicroShunt in the Treatment of Glaucoma: Insights from a Second Delphi Consensus Panel.Ophthalmology and therapy · 2024Article
- Article
- Efficacy and Safety of PreserFlo MicroShunt Implantation and Its Effects on Intraocular Inflammation through Laser Flare Photometry.Journal of ophthalmology · 2024Article
- PRESERFLO MicroShunt implantation versus trabeculectomy for primary open-angle glaucoma: a two-year follow-up study.Eye and vision (London, England) · 2023Article
Corrections and comments
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsTo evaluate 1-year success rates and safety profile of Preserflo™ Microshunt in glaucoma patients.
methodsRetrospective multicentre cohort study of 100 consecutive eyes (91 patients) from four tertiary-referral glaucoma centres. Four intraocular pressure (IOP) criteria were defined: A: IOP ≤ 21 mmHg+IOP reduction ≥20% from baseline; B: IOP ≤ 18 mmHg+IOP reduction ≥20%; C: IOP ≤ 15 mmHg+IOP reduction ≥25%; D: IOP≤12 mmHg+IOP reduction ≥30%. Success was defined as qualified or complete based on whether reached with or without medication. Primary outcome was success according to the above criteria. Secondary outcomes included: IOP, best-corrected visual acuity (BCVA), medication use, complications, postoperative interventions, and failure-associated factors.
resultsQualified and complete success rates (95% CI) at 12 months were 74%(66-83%) and 58%(49-69%) for criterion A, 72%(63-82%) and 57%(48-68%) for B, 52%(43-63%) and 47%(38-58%) for C, 29%(21-40%) and 26%(19-36%) for D. Overall median (interquartile range (IQR)) preoperative IOP decreased from 21.5(19-28) mmHg to 13(11-16) mmHg at 12 months. BCVA was not significantly different up to 12 months (p = 0.79). Preoperative median (IQR) number of medications decreased from 3 (2-3) to 0 (0-1) at 12 months. Twelve eyes underwent needling, five surgical revision and one device removal due to corneal oedema. There were no hypotony-related complications. Non-Caucasian ethnicity was the only risk factor consistently associated with increased failure.
conclusionsPreserflo™ Microshunt is a viable surgical option in glaucoma patients, with reasonable short-term success rates, decreased medications use, excellent safety profile, smooth postoperative care, and rapid learning curve. Success rates for the most stringent IOP cutoffs were modest, indicating that it may not be the optimal surgery when very low target IOP is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.